Evolution of Pain From Herpes Zoster

Status Completed

Clinical Trial Summary

Evolution of pain and neural injury will be evaluated at 2 years or longer after the onset of AHZ by multiple measures. Assessments at 2 years or longer will be compared to those collected during the first 6 months after HZ in order to test whether or not sensory function and cutaneous innervation continues to normalize beyond 6 months in subjects who recover from HZ without severe PHN.

Clinical Trial Description

Pain, nerve trunk inflammation, and neuronal injury are hallmarks of acute herpes zoster (AHZ). We hypothesize that the development of post-herpetic neuralgia (PHN) strongly depends on two factors: 1) the severity of the initial neural injury and 2) the ability to recover from the initial neural injury. To test this hypothesis, we will prospectively follow 150 patients at high risk for development of PHN. Evolution of pain and neural injury will be evaluated at 2-6 weeks, 6 weeks, 3 months, 6 months and at 2 years or longer after the onset of AHZ by multiple measures. Assessments at 2 years or longer will be compared to those collected during the first 6 months after HZ in order to test whether or not sensory function and cutaneous innervation continues to normalize beyond 6 months in subjects who recover from HZ without severe PHN. Preliminary analysis of study data showed reduced innervation in HZ skin, mirror image skin and distant control skin in the acute phase of HZ that was not specific to the persistence of pain at 3 months. The innervation appeared to recover more fully by 6 months in distant control skin than in mirror-image skin and HZ skin, despite the fact that the subjects were continuing to experience a further reduction in their zoster-associated pain. This suggests that the symptoms of pain and sensory dysfunction are not due to a mere loss in overall innervation density. The proposed subsequent ≥ 2 year study visit and analysis will allow us to directly correlate pain resolution with resolution of sensory and innervation abnormalities. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00305357
Study type	Observational
Source	University of California, San Francisco
Contact
Status	Completed
Phase
Start date	November 2001
Completion date	December 2006

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01944150` - Association of Transcutaneous Electrical Nerve Stimulation and Hypnosis	N/A
Completed	`NCT00159666` - Study of Pregabalin Therapy for Pain Relief in Subjects With Post-Herpetic Neuralgia	Phase 4
Not yet recruiting	`NCT03120962` - Effect of Early Use of Oxycodone During the Acute Phase of Herpes Zoster on Preventing Postherpetic Neuralgia	N/A
Completed	`NCT02701374` - Efficacy and Safety of TRK-700 in Patient With Post-Herpetic Neuralgia	Phase 2
Terminated	`NCT03094195` - Dose Response Study of EMA401 in Patients With Post-herpetic Neuralgia (PHN)	Phase 2
Completed	`NCT02318719` - DS-5565 Phase III Study for Post-herpetic Neuralgia	N/A
Completed	`NCT01752699` - Methadone in Post-Herpetic Neuralgia Pain	Phase 3
Completed	`NCT01250561` - Reduction of Postherpetic Neuralgia in Herpes Zoster	N/A
Completed	`NCT02607280` - DS-5565 Phase III Study for Renal Impairment in Japanese Subjects	Phase 3
Completed	`NCT01037088` - Effects of Vaporized Marijuana on Neuropathic Pain	Phase 1/Phase 2
Completed	`NCT02633306` - Transcranial Magnetic Stimulation for Facial Pain	N/A
Recruiting	`NCT05593237` - Transcranial Magnetic Stimulation for Chronic Neuropathic Pain	N/A
Completed	`NCT01848730` - Efficacy and Safety of CNV2197944 Versus Placebo in Patients With Post-herpetic Neuralgia	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.